Regeneron Pharmaceuticals, known by the ticker
REGN, has been facing multiple developments recently. This includes fresh investments from
Congress Wealth Management LLC and
D.A. Davidson & CO along with a sizable sell-off from
Orion Portfolio Solutions LLC. There have been reports of insider selling, possibly signaling caution. Legal troubles are also on the horizon, with the Department of Justice accusing the company of
drug-price manipulation. Notably, the company's
blockbuster eye drug has seen weaker sales due to inventory impact. It is also dealing with a setback for its blood cancer therapy as the FDA raised trial concerns. Despite these challenges, investors who invested in Regeneron five years ago would have enjoyed a
133% gain. Furthermore, its stock, which recently hit a record high, has been performing well, outperforming the industry year-to-date. However, the company is currently seen as potentially overpriced. Notably, REGN just announced positive data on an
oncology candidate contributing to the rally in its stock.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 08 Sep 2023 07:00:00 GMT to Thu, 30 May 2024 21:40:00 GMT -
Rating 5
- Innovation 7
- Information 7
- Rumor 1
